Mitiglinide: A novel agent for the treatment of type 2 diabetes mellitus

Annals of Pharmacotherapy

Volumn 44, Issue 10, 2010, Pages 1615-1623

  Phillippe, Haley M ^a,b   Wargo, Kurt A ^a,b  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Meglitinide; Mitiglinide

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIDIABETIC AGENT; FIBRIC ACID DERIVATIVE; GLINSUNA; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; METGUNA; MITIGLINIDE; MITIGLINIDE PLUS METFORMIN; NATEGLINIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; UNCLASSIFIED DRUG; VALPROIC ACID;

ADD ON THERAPY; CLINICAL TRIAL; CONSTIPATION; DIABETIC DIET; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; EVENING DOSAGE; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSOMNIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; MEDLINE; MONOTHERAPY; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PAIN; PANCREAS CARCINOMA; PANCREAS ISLET BETA CELL; PERIPHERAL EDEMA; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THIRST; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; ISOINDOLES;

EID: 77957722846     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P136     Document Type: Review

References (23)

1. World Health Organization. Diabetes: what is diabetes? www.who.int/mediacentre/factsheets/fs312/en/ (accessed 2010 Feb 22).
2. Centers for Disease Control and Prevention: national diabetes fact sheet, 2007. http://apps.nccd.cdc.gov/ddtstrs/FactSheet.aspx (accessed 2010 Feb 22).
3. Kaku K, Tanaka S, Origasa H, Kikuchi M, Akanuma Y. Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. Endocr J 2009;56:657-64.
4. Gao X, Mitiglinide Versus Nateglinide Comparison Study Group. Multicentre, double-blind, randomized study of mitiglinide compared with nateglinide in type 2 diabetes mellitus patients in China. J Int Med Res 2009;37:812-21.
5. Chiasson J, Gomis R, Hanefeld M, et al. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to prevent non-insulin- dependent diabetes mellitus. Diabetes Care 1998;21:1720-5.
6. KISSEI R&D Pipeline. www.kissei.co.jp/e-contents/relation/pipeline. html (accessed 2010 Feb 22).
7. Elixir Pharmaceuticals Product Pipeline. www.elixirpharm.com/product/ index.html (accessed 2010 Feb 22).
8. Pratley RE, Foley JE, Dunning BE. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des 2001;7:1375-97.
9. Prescribing information. Prandin (repaglinide). Princeton, NJ: Novo Nordisk, Inc., March 2010.
10. Prescribing information. Starlix (nateglinide). East Hanover, NJ: Novartis Pharma Stein AG, July 2008.
11. Malaisse W. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2003;2:401-14.
12. Yu L, Lu S, Lin Y, Zeng S. Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol 2007;73:1842-51.
13. Wilkinson GR. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York, NY: McGraw-Hill, 2001:3-29.
14. Yamada S, Watanabe M, Funae O, et al. Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus. Intern Med 2007;46:1893-7.
15. Kumashiro N, Yoshihara T, Kanazawa Y, et al. Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. Endocr J 2007;54:163-6.
16. Malaisse WJ. Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. Expert Opin Pharmacother 2008;9:2691-8.
17. Yoshihara T, Kumashiro N, Kanazawa Y, et al. Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Endocr J 2006;53:67-72.
18. Kaku K, Tanaka S, Origasa H, Kikuchi M, Akanuma Y. Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy. Endocr J 2009;56:739-46.
19. Konya H, Miuchi M, Konishi K, et al. Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. J Int Med Res 2009;37:1904-12.
20. Nakano T, Inoue I, Satoh K, et al. Treatment with glimepiride, but not mitiglinide and short-acting insulin, resists body weight and abdominal fat reduction under dietary energy restriction. J Atheroscler Thromb 2009;16:63-6.
21. Assaloni R, Da Ros R, Quagliaro L, et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 2005;48:1919-24.
22. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203.
23. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13:3-68.